Clinical distribution and antimicrobial resistance of 98 Burkholderia cepacia strains
Author:
Affiliation:

Clc Number:

R378

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    ObjectiveTo analyze antimicrobial resistance of clinically isolated Burkholderia cepacia(B. cepacia), and provide evidence for clinical rational antimicrobial use.MethodsB. cepacia isolated from clinical specimens between January 2013 and December 2014 were analyzed retrospectively, antimicrobial susceptibility results were statistically analyzed.ResultsA total of 98 isolates of B. cepacia between January 2013 and December 2014 were isolated, the main specimen was sputum(n=86, 87.76%), the main department distribution was intensive care unit(n=46, 46.94%),resistance rate of B. cepacia to ticarcillin / clavulanic acid was highest(73.47%), resistance rates to piperacillin / tazobactam and cefoperazone / sulbactam were both 16.33%,resistance rate to minocycline was the lowest(5.10%).ConclusionInfection caused by B. cepacia is high, prevention and control of healthcareassociated infection should be strengthened, early etiological examination should be performed, antimicrobial treatment should be combined with antimicrobial susceptibility results.

    Reference
    Related
Get Citation

付玉华,朱文秀,杜希利,等.98株洋葱伯克霍尔德菌临床分布及耐药性[J].中国感染控制杂志英文版,2017,16(3):215-217. DOI:10.3969/j. issn.1671-9638.2017.03.006.
FU Yuhua, ZHU Wenxiu, DU Xili, et al. Clinical distribution and antimicrobial resistance of 98 Burkholderia cepacia strains[J]. Chin J Infect Control, 2017,16(3):215-217. DOI:10.3969/j. issn.1671-9638.2017.03.006.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:February 25,2016
  • Revised:April 29,2016
  • Adopted:
  • Online: March 31,2017
  • Published: